Dermatology

Boni Elewski, MD, and Benjamin Kaffenberger, MD, and Carly Elston, MD, reviews the symptoms that patients with generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP), acrodermatitis continua of Hallopeau, Steven-Johnson syndrome (SJS), toxic epidermal necrolysis, linear IgA bullous dermatosis (LABD), and hidradenitis suppurativa typically present with in a dermatology clinic.

Recent data showed that a new HS-IGA tool for hidradenitis suppurativa addressed several concerns of prior tools but also maintained certain limitations.

Experts discuss some rare dermatological disorders that critical care physicians may see in the emergency room setting or dermatologists may see in their clinics along with the prevalence of these diseases.

The research method, which provides better context into patient and caregiver perspective on the field, has increased nearly two-fold in prevalence since 2020.

Mehmi described some of the major challenges to diagnosing mucosal melanoma in patients, as well as the small amount of data around treating the rare but dangerous condition.

A retrospective analysis shows patients unresponsive to either secukinumab, ixekizumab or brodalumab may benefit from another of them.

This interview featured Mehmi discussing a less well-known form of melanoma known as mucosal melanoma, a condition which he believes needs to be researched in greater depth.

Research indicates greater expertise in the non-invasive technique for diagnosis of basal cell carcinoma may be useful, although remote supervision of novice assessors by an expert may also help.

New data on US Medicare beneficiaries indicates that the head and neck region of the body was most commonly affected by squamous cell carcinomas compared to other areas.

Research indicates that despite reports of high psychological stress among women in their 20s and 30s in China and Japan, awareness of stress’s effects on aging remain higher among health professionals.

New study data re-evaluating current guidelines for T1a melanoma excisions indicate that 5-mm margins may be adequate in order to maintain lower risk levels for melanoma recurrence.

In another interview segment, a discussion was held with medical student Brenda Abreu Molnar about her experiences with epidermolysis bullosa patients and the SPD’s 2022 Medical Student Mentorship Award.

In this interview, medical student Brenda Abreu Molnar discussed the SPD’s 2022 Medical Student Mentorship Award and her experiences leading up to it.

A questionnaire analysis from Germany shows patients are more likely to be satisfied with the safety and convenience of their topical drugs than they are their effectiveness in treating psoriasis.

From a novel topical gene therapy to a multi-pathway targeting HF drug, the second quarter of 2023 is laden with interesting regulatory decisions.

New research on a patient with recalcitrant eosinophilic annular erythema who had been successfully treated with benralizumab suggests a therapeutic possibility for EAE patients.

New data shows that there are several major reasons for the perceptions of patients with hidradenitis suppurativa viewing their own access to healthcare as problematic.

Expert dermatologists discuss the importance of continued education for physicians treating patients with alopecia areata.

Dr. Brett King shares novel mechanisms of action under research for the treatment of alopecia areata in different age groups.

The expert panel discusses the secondary analysis from the phase 3 BRAVE clinical trials of baricitinib in alopecia areata.

Drs. Raj Chovatiya, George Han, and Brett King discuss the use of baricitinib for the treatment of moderate to severe alopecia areata.

The expert panel highlights the psychosocial burden of alopecia areata on patients and discusses the current treatment paradigm.

Patients with dystrophic epidermolysis bullosa face near-constant pain and discomfort. While there are several measures clinicians have to help them, a curative treatment remains elusive.

During his latest interview, Lal further explored the topic of recessive dystrophic epidermolysis bullosa and his experiences helping patients with the rare condition.

A silent disease characterized as a chronic cutaneous neuropathy, notalgia paresthetica has an unmet need yet to be fully understood and, dermatologists argue, an FDA-approved treatment could help improve understanding of the etiology and prevalence of this disease.